News

IVD Research Inc., a contract development and manufacturing (CDMO)  firm in Carlsbad, California has licensed a novel biomarker for onchocerciasis—better known as river blindness—from Scripps Research in La Jolla, California. The reagent, developed in the laboratory of Kim Janda, PhD, a professor of chemistry at Scripps Research, will allow clinicians to monitor active infections of onchocerciasis.

"This could give us a way to kill tumors without harming normal cells..."

Collaboration will focus on switchable CAR-T therapies aimed primarily at solid tumors.

Proteins with a selective targeting system can zero in on a protein found on the surface of several types of cancer cells.

Calibr has now identified and repurposed an FDA-approved drug, clofazimine, used for decades to treat leprosy, as a potential new treatment for cryptosporidiosis.

More than 27 million people live with osteoarthritis, and it turns out, elite racing and jumping horses do, too.

"These results lay the groundwork for the next steps toward FDA approval."

"The heroin vaccine is one step closer to clinical evaluation," says Candy S. Hwang, PhD, first author of the study and a research associate at TSRI.

Known as KA34, the drug is a small molecule that “encourages adult stem cells already residing in the joint to mature toward chondrocytes, the cells that produce and maintain healthy cartilage..."

“This points the way toward a new therapeutic opportunity,” says lead investigator Ben Shen.

Ninety-one Americans die every day from opioid overdoses—deaths caused when opiates like oxycontin, heroin and fentanyl slow and eventually stop a person’s breathing.

“This drug candidate is poised to go into clinical trials, and we think it might be effective against multiple forms of autism."

"The success of ozanimod shows that academia and the NIH can make transforming discoveries that benefit patients and those that care for them."

Scientists at Scripps Research have discovered a compound that in laboratory tests irreversibly stops the growth of certain aggressive, treatment-resistant tumor cells.

"Because of our aging population, these kinds of therapeutics are in great demand..."

The insights could help researchers design new drugs with better efficacy and fewer side effects.

A new peptide probe may hold the key to better understanding amyloid diseases.

Scientists from the Florida campus of The Scripps Research Institute have identified a class of compounds that significantly delays the onset of several age-related symptoms

New method provides researchers with a new way to understand such drug compounds, especially where individual components or metabolites interact to produce the complete effects of psychoactive species.

World-class research institute and new innovation center partner to accelerate early translational research.

Scientists at Scripps Research have given new superpowers to a lifesaving antibiotic called vancomycin, an advance that could eliminate the threat of antibiotic-resistant infections for years to come.

Leaders in basic and translational research at TSRI and Calibr will provide target materials and relevant know‐how to prosecute drug targets of interest.

Initial demonstrations yield compounds with promise for treating COPD, cystic fibrosis and other lung disorders.

Scientists may have found a new tool for studying—and maybe even treating—Type 2 diabetes, the form of diabetes considered responsible for close to 95 percent of cases in the United States.